Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Victoza is a daily injection for type 2 diabetes that also produces moderate weight loss as a secondary effect. It contains liraglutide, the same active ingredient as Saxenda, at a lower dose and with a different approved purpose.
Understanding that relationship clears up most of the confusion around this drug. Same molecule, two brand names, two doses, two approved uses.
What Victoza contains
Victoza is liraglutide, dosed at 0.6 mg, 1.2 mg or 1.8 mg daily. It is approved to improve blood sugar control in adults with type 2 diabetes.
Saxenda is the same liraglutide, dosed up to 3.0 mg daily, approved for weight management.
Novo Nordisk markets them separately because the approved uses differ. Chemically, there is no difference between them beyond concentration and pen design.
This matters practically. You should not use Victoza as a substitute for a weight management dose, and you should not assume Saxenda's weight loss results apply at Victoza's lower doses. They do not.
How liraglutide works
Liraglutide imitates GLP-1 (glucagon-like peptide-1, a hormone your intestine releases after you eat). Natural GLP-1 breaks down within a couple of minutes. Liraglutide is engineered to last around 13 hours, which is why one daily injection works.
It acts in several places.
In the pancreas. It increases insulin release when blood sugar is high, and reduces glucagon, a hormone that pushes blood sugar up. Importantly, this effect is glucose-dependent, meaning it largely switches off when blood sugar is normal. That is why liraglutide alone rarely causes dangerously low blood sugar.
In the stomach. It slows how quickly food leaves your stomach, which flattens the blood sugar spike after meals and increases fullness.
In the brain. It reduces appetite signalling in the hypothalamus. This is the effect that produces weight loss.
What Victoza does for blood sugar
Victoza lowers HbA1c, the measure of average blood sugar over roughly three months. Typical reductions in trials fall in the range of 1.0 to 1.5 percentage points depending on dose and starting level.
It is used alongside diet and exercise, often added to metformin when metformin alone is not achieving targets.
Because its glucose-lowering action is dependent on blood sugar being elevated, the risk of hypoglycaemia is low when Victoza is used on its own. That risk rises considerably if it is combined with insulin or sulfonylureas, and those doses usually need reducing.
The cardiovascular finding
The most significant Victoza result was not about blood sugar at all.
The LEADER trial, published in the New England Journal of Medicine in 2016, followed 9,340 people with type 2 diabetes at high cardiovascular risk. It compared liraglutide against placebo.
The primary outcome, a combination of cardiovascular death, non-fatal heart attack and non-fatal stroke, occurred in 13.0 percent of the liraglutide group against 14.9 percent on placebo. The hazard ratio was 0.87.
That is a meaningful reduction in serious cardiovascular events, and it changed how the drug class is viewed. GLP-1 medications moved from being purely glucose-lowering agents to drugs with demonstrated cardiovascular benefit in high-risk patients.
Weight loss on Victoza
Weight loss happens on Victoza, but expectations need calibrating against the dose.
At 1.8 mg, typical weight loss in diabetes trials falls in the range of 2 to 3 kg. This is a genuine effect and it is useful, particularly because most other diabetes drugs either have no weight effect or cause weight gain.
But it is not comparable to weight management dosing. Saxenda at 3.0 mg produced an average 8.4 kg loss in the SCALE trial. The higher dose does considerably more work.
If weight loss is your primary goal, Victoza is the wrong tool. It was not designed for that and its dose ceiling limits what it can achieve.
How you take it
Victoza starts at 0.6 mg daily for at least one week. This starting dose is not intended to control blood sugar. Its purpose is to let your digestive system adapt.
It then increases to 1.2 mg. If more glucose lowering is needed, it can go to 1.8 mg after another week or more.
Injection goes into the abdomen, thigh or upper arm, once daily, at any time of day, with or without food. Keeping to a consistent time helps you remember it.
Unopened pens are refrigerated. Once in use, a pen is kept at room temperature or refrigerated and discarded after 30 days.
Side effects
The pattern is standard for the drug class.
Nausea is the most common, particularly in the first weeks and after each dose increase. Diarrhoea, vomiting, constipation, headache and reduced appetite are also frequently reported.
Most of these settle. The gradual dose escalation exists specifically to reduce their severity.
Less common but serious concerns include pancreatitis, which presents as severe persistent abdominal pain often radiating to the back, and gallbladder problems. Both need prompt medical assessment rather than waiting.
Victoza is not used in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. It is not used in type 1 diabetes or diabetic ketoacidosis, and not during pregnancy.
Victoza in Pakistan
Availability is inconsistent. Liraglutide products in Pakistan arrive through import channels, require refrigerated storage, and are priced against the dollar.
For someone managing type 2 diabetes, this is a supply problem with real clinical consequences. Interrupted diabetes treatment is not a minor inconvenience.
For someone whose main goal is weight loss rather than glucose control, Victoza was never the right choice regardless of availability. The dose is simply too low for that purpose.
Where weight is the target and injectable options are out of reach, the METASLIM™ program offers GLP-1 pathway support through sublingual drops instead. It is a physician-reviewed supplement rather than a pharmaceutical GLP-1 receptor agonist, so it does not replace diabetes medication and should never be used as a substitute for prescribed glucose control. What it addresses is the appetite side of the equation, with a physician reviewing suitability before anything ships.
Anyone managing diabetes should be making these decisions with their treating doctor rather than independently. Before setting any weight target, calculate your BMI to establish where you actually stand.
For the wider context, our guide to Saxenda covers the weight management version of this same drug, and what a GLP-1 receptor agonist is explains the class as a whole.
The summary
Victoza is a well-established type 2 diabetes medication with proven cardiovascular benefit from the LEADER trial. It produces modest weight loss of roughly 2 to 3 kg as a secondary effect.
It is the same drug as Saxenda at a lower dose. If your goal is diabetes control, it is a sound option where you can obtain it. If your goal is weight loss, the dose is too low to deliver what you are looking for.
To compare structured weight loss options rather than diabetes medications, see the current program price and what it covers.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.